Jiayin Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiayin Sun has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Chao Huang
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
14 shared publications - Guosong Jiang
Department of Urology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China
14 shared publications - Huayuan Zhao
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
14 shared publications - Hui Zhang
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
14 shared publications - Junping Li
Department of Urology, Guangdong Second Provincial General Hospital, Guangzhou, China
14 shared publications - Miao Wang
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
14 shared publications
Latest Publications
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Effects of DMSO, MCHA, Erdafitinib and combined treatment on the indicators of cardiac, hepatic, and renal function of mice.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Effects of DMSO, MCHA, Erdafitinib and combined treatment on the indicators of cardiac, hepatic, and renal function of mice.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementay Table 1 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
The sequences of primers used in this study.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementay Table 1 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
The sequences of primers used in this study.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S5 shows that HMGA2 directly binds to the promoter of EGFR.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S5 shows that HMGA2 directly binds to the promoter of EGFR.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Determination of the protein potentially regulated by SRM using Venn analysis.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Determination of the protein potentially regulated by SRM using Venn analysis.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S7 shows that SRM inhibitor MCHA is synthetic lethal with Erdafitinib.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S7 shows that SRM inhibitor MCHA is synthetic lethal with Erdafitinib.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S2 shows that SRM loss enhances erdafitinib efficacy in bladder cancer.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S2 shows that SRM loss enhances erdafitinib efficacy in bladder cancer.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S4 shows that SRM supports the efficient translation of HMGA2 by eIF5A hypusination.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S4 shows that SRM supports the efficient translation of HMGA2 by eIF5A hypusination.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementay Table 2 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
The sequences of shRNA and sgRNA used in this study.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementay Table 2 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
The sequences of shRNA and sgRNA used in this study.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Identification of synthetic lethal genes for erdafitinib in MGH-U3 and SW780 cells using Venn analysis.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Identification of synthetic lethal genes for erdafitinib in MGH-U3 and SW780 cells using Venn analysis.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S3 shows that SRM depletion sensitizes bladder cancer cells to erdafitinib via HMGA2.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S3 shows that SRM depletion sensitizes bladder cancer cells to erdafitinib via HMGA2.